Kisspeptin sits at the very top of the chain that runs human reproduction. A short fragment of it, called kisspeptin-10, has become one of the most studied peptides in modern endocrinology.
What Is Kisspeptin?
Kisspeptin is a protein encoded by the KISS1 gene. The body cuts it into shorter active pieces. The most studied piece is kisspeptin-10 (also called KP-10 or metastin 45-54), a ten-amino-acid fragment from the C-terminal end.
This small fragment carries most of the parent protein's signaling power. Researchers use it because it is easier to work with than the full-length molecule and binds the same target.
How Kisspeptin Works
Kisspeptin-10 binds a receptor called KISS1R on neurons in the hypothalamus. When it binds, those neurons release gonadotropin-releasing hormone (GnRH).
GnRH then travels to the anterior pituitary, which releases two more hormones: luteinizing hormone (LH) and follicle-stimulating hormone (FSH). LH and FSH reach the testes or ovaries, where they drive testosterone or estrogen production. This whole chain is called the HPG axis (hypothalamic-pituitary-gonadal axis).
Kisspeptin sits above all of it. That is why researchers call it a "master regulator" of reproduction (de Roux et al., 2003; Seminara et al., 2003).
Why the Upstream Position Matters
Direct testosterone or estrogen administration adds hormone from the outside. Kisspeptin works differently. By acting at the top of the cascade, it prompts the body to make its own sex hormones through the natural pathway.
This upstream role has drawn attention in research on puberty timing, hypogonadism, and certain forms of infertility. Small clinical studies in men with low testosterone and women with reproductive disorders have shown that kisspeptin can stimulate the LH and FSH response (Jayasena et al., 2014).
Dosing Patterns in Research
The natural HPG axis is pulsatile. GnRH is released in short bursts every one to two hours, not as a steady stream. Constant high signaling actually shuts the system down, a quirk used clinically with GnRH agonists.
Investigators have found that pulsatile kisspeptin dosing, small amounts given on a schedule, mirrors physiology more closely than a single large dose. Pulse-style protocols tend to produce cleaner LH responses in study subjects.
Most kisspeptin work to date is preclinical or in small human trials. Long-term safety, optimal pulse intervals, and effects in different patient groups are still being studied. These compounds are sold strictly for in vitro laboratory research and are not approved for human consumption.